. 2012 May 15;2(2):172–176. doi: 10.1038/kisup.2012.17

Table 7. Cytotoxic therapy in SRNS.

Author	N	Intervention	Control	Remission complete or partial	RR for remission	Conclusion
ISKDC 1974⁹⁷	31	Cyclophosphamide p.o. + prednisone 3 mo	Prednisone 3 mo	10 (56%) vs. 6 (46%)	1.20 (0.59–2.47)	ND
Tarshish 1996⁹⁸	53	Cyclophosphamide po x 3 mo + prednisone 12 mo q.o.d.	Prednisone 12 mo q.o.d.	16 (50%) vs. 12 (57%)	0.88 (0.53–1.45)	ND

ISKDC, International Study of Kidney Disease in Children; ND, not determined; p.o., orally; q.o.d., every other day; SRNS, steroid-resistant nephrotic syndrome.